Evidence map›Paper›PMID 22357497›Full record

ArticleJournal of clinical microbiology2012

Clinical validation of a point-of-care multiplexed in vitro immunoassay using monoclonal antibodies (the MSD influenza test) in four hospitals in Vietnam.

H Rogier van Doorn, Nguyen van Kinh, Ha Manh Tuan, Tran Anh Tuan, Ngo Ngoc Quang Minh, Juliet E Bryant, Vu thi Ty Hang, Le thi Tham Uyen, Le Quoc Thinh, Tran thi Ngoc Anh and 9 more

Open access · bronzeAbstract readComparative StudyEvaluation StudyMulticenter Study
In one paragraph

Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Single Domain Antibodies as New Biomarker Detectors.Diagnostics (Basel, Switzerland) · 2017
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

H Rogier van DoornSouth East Asian Infectious Diseases Clinical Research Network, Ho Chi Minh City, Vietnam. hrogier@gmail.com
Nguyen van Kinh
Ha Manh Tuan
Tran Anh Tuan
Ngo Ngoc Quang Minh
Juliet E Bryant
Vu thi Ty Hang
Le thi Tham Uyen
Le Quoc Thinh
Tran thi Ngoc Anh
Nguyen Phu Huong Lan
Nguyen Vu Trung
Walter Taylor
Laura Merson
Heiman F L Wertheim
Jeremy Farrar
Marcel Wolbers
Nguyen van Vinh Chau
Menno D de Jong
Oxford University Clinical Research Unit · VNHospital for Tropical Diseases · VNChildren's Hospital 1 · VNChildren's Hospital 2 · VN

Funding

PHS HHS HHS200-2007-19346PHS HHS HHSN272-2009-00001LWellcome Trust 077078/Z/05/ZWellcome Trust 093724
6 · The paper itself

Abstract

Point-of-care (POC) diagnostic tests for influenza can considerably shorten the time to clinical decision making. An investigational POC test based on a multiplexed immunoassay was developed by Meso Scale Diagnostics, LLC (MSD), with the objective to make a more sensitive rapid test that can also subtype influenza A viruses (1977 H1, H3, and H5). Between February and November 2010, we conducted a prospective multicenter study at four hospitals in Vietnam and compared the performance of this test to that of the WHO/CDC real-time reverse transcriptase PCR (RT-PCR) on nasal and throat swab specimens from patients presenting with influenza-like illness. Five hundred sixty-three adults and children with a median age of 25 months were enrolled. Sensitivity and specificity of the test with combined results from nasal and throat swab samples were 74.0% (131/177) and 99.7% (351/352), respectively, compared to RT-PCR. The POC test was as sensitive for influenza virus B as for influenza virus A (74.4% [64/86] versus 73.6% [67/91]). The positivity rate was associated with lower cycle threshold values (a marker for higher viral loads), sample type (73.6% for nasal swab versus 52.4% for throat swab), and younger age. A total of 210 (18.7%) out of 1,126 MSD tests failed, and for 34 (6%) of patients, both test samples failed (these were excluded from the performance analysis). Subtyping could be assessed only for influenza virus A/H3N2, as 1977 H1N1 was not circulating at the time and no H5N1-infected patients were enrolled, and was successful only in 9/54 patients infected with H3 influenza virus who had a positive POC test result for influenza virus A. This novel POC test provided highly sensitive detection of influenza viruses A and B compared to the reported sensitivities of other rapid tests. However, 18.7% of tests failed for technical reasons and subtyping for H3 was poor. Drawbacks to the technology include the requirement for a dedicated reader instrument and the need for continual updating of subtyping antibodies within the test array.

Indexed as

Point-of-Care SystemsAdolescentAdultAgedAntibodies, MonoclonalAntibodies, ViralAntigens, ViralChildChild, PreschoolFemaleHospitalsHumansImmunoassayInfantInfluenza, HumanMaleAntibodies, MonoclonalAntibodies, ViralAntigens, Viral

Identifiers

PMID22357497
PMCPMC3347120
OpenAlexW2089698043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.